Cytosorbents Corp
For the period ended Nov 13, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 13, 2025 · Filed Nov 13, 2025
Use the contents to explore the available documents and sections.
CTSO$4.80+4.3%Stored close · as of Nov 6, 2026
Contents
EX-99 · (in thousands, except share data)
(in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Par Value | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of June 30, 2025 (unaudited) | 62,610,376 | $63 | $319,023 | $(3,960) | $(303,540) | $11,586 |
| Stock-based compensation | 183,929 | — | 488 | — | — | 488 |
| Foreign translation adjustment | — | — | — | 116 | — | 116 |
| Net loss | — | — | — | — | (3,170) | (3,170) |
| Balance at September 30, 2025 (unaudited) | 62,794,305 | $63 | $319,511 | $(3,844) | $(306,710) | $9,020 |
| Balance at December 31, 2024 | 54,830,146 | $55 | $310,809 | $4,252 | $(304,009) | $11,107 |
| Stock-based compensation | 297,160 | 1 | 1,878 | — | — | 1,879 |
| Issuance of common stock and warrants from rights offerings, net of fees incurred | 6,249,791 | 6 | 5,386 | — | — | 5,392 |
| Issuance of common stock from exercise of warrants | 1,417,208 | 1 | 1,438 | — | — | 1,439 |
| Foreign translation adjustment | — | — | — | (8,096) | — | (8,096) |
| Net loss | — | — | — | — | (2,701) | (2,701) |
| Balance as of September 30, 2025 (unaudited) | 62,794,305 | $63 | $319,511 | $(3,844) | $(306,710) | $9,020 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Par Value | Capital | Income | Deficit | Equity | |
| Balance as of June 30, 2024 (unaudited) | 54,306,415 | $54 | $308,874 | $2,173 | $(293,674) | $17,427 |
| Stock-based compensation | — | — | 891 | — | — | 891 |
| Foreign translation adjustment | — | — | — | (2,330) | — | (2,330) |
| ATM activation fees | — | — | (41) | — | — | (41) |
| Issuance of restricted stock units | 194,198 | — | 204 | — | — | 204 |
| Net loss | — | — | — | — | (2,768) | (2,768) |
| Balance at September 30, 2024 (unaudited) | 54,500,613 | $54 | $309,928 | $(157) | $(296,442) | $13,383 |
| Balance at December 31, 2023 | 54,240,265 | $54 | $306,187 | $529 | $(283,290) | $23,480 |
| Stock-based compensation | — | — | 2,840 | — | — | 2,840 |
| Foreign currency translation adjustment | — | — | — | (686) | — | (686) |
| Issuance of common stock offerings, net of fees | 53,290 | — | 12 | — | — | 12 |
| Warrants issued in connection with long-term debt | — | — | 691 | — | — | 691 |
| Issuance of restricted stock units | 207,058 | — | 198 | — | — | 198 |
| Net loss | — | — | — | — | (13,152) | (13,152) |
| Balance as of September 30, 2024 (unaudited) | 54,500,613 | $54 | $309,928 | $(157) | $(296,442) | $13,383 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.